• Molecular NameCefpodoxime_proxetil
  • SynonymCefpodoxime; CPDX-PR; RU 51807
  • Weight557.605
  • Drugbank_IDN/A
  • ACS_NO87239-81-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.18
  • pkaN/A
  • LogD (pH=7, predicted)1.18
  • Solubility (experiment)Poorly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-5.23
  • LogSw (predicted, AB/LogsW2.0)0.5
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors3
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds13
  • TPSA234.51
  • StatusN/A
  • AdministrationN/A
  • PharmacologyAnti-Bacterial Agents
  • Absorption_value50.0
  • Absorption (description)Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically. Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime in vivo.
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding27.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse events thought possibly or probably related to cefpodoxime were: diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache, rash, vomiting
  • LD50 (rat)N/A
  • LD50 (mouse)N/A